tbuckley/cabot-search huggingface dataset:
High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong
Authors: Sunny H. Wong, Margaret Ip, Peter M. Hawkey, Norman Lo, Katie Hardy, Susan Manzoor, Wyman W.M. Hui, Kin-wing Choi, Rity Y.K. Wong, Irene M.H. Yung, Catherine S.K. Cheung, Kelvin L.Y. Lam, Thomas Kwong, William K.K. Wu, Siew C. Ng, Justin C.Y. Wu, Joseph J.Y. Sung, Nelson Lee
Journal: Journal of Infection (2016)
Lymphoscintigraphy in Differentiated Thyroid Cancer
Authors: Isabella Merante Boschin, Maria Rosa Pelizzo, Francesco Giammarile, Domenico Rubello, Patrick M. Colletti
Journal: Clinical Nuclear Medicine (2015)

There is considerable variability in the surgical approach to differentiated thyroid cancer regarding the decision to explore and remove central or central and lateral compartment lymph nodes. Much as sentinel lymph node sampling has improved the decision to remove axillary nodes for breast cancer, vital dye and lymphoscintigraphy with lymph node sampling may direct the surgical approach to differentiated thyroid cancer.
Changes in prevention and outbreak management of Legionnaires’ disease in the Netherlands between two large outbreaks in 1999 and 2006
Authors: G J Sonder, J A van den Hoek, L P Bovée, F E Aanhane, J Worp, M Du Ry van Beest Holle, J E van Steenbergen, J W den Boer, E P Ijzerman, R  A Coutinho
Journal: Eurosurveillance (2008)

Binary file ES_Abstracts_Final_ECDC.txt matches
Abstract P1-07-18: Breast cancer in young patients, twelve years of experience in a single institution
Authors: ZD Morante, C Pacheco, RS Limón, S Neciosup, HL Gomez
Journal: Cancer Research (2016)

Abstract Breast cancer is very rare in young women and has a more aggressive biological behavior and a worse prognosis than in older premenopausal women. This study was designed to determine and evaluate the features of breast cancer in young patients less than 35 years old at the Instituto Nacional de Enfermedades Neoplásicas, Lima - Perú. Medical records of 115 patients less than 35 years old with breast cancer, whom were diagnosed and received a kind of treatment, even surgery, chemotherapy, radiotherapy or all of them at the Instituto Nacional de Enfermedades Neoplásicas Lima-Perú, between January 2000 and December 2012, were reviewed. Triple negative breast cancer (38.3%) is the most common subtype cancer and its presentation is in a lower age compared with the others subtypes (27.1 years vs 28.5 years p: 0.047). The high histological grade was more frequent in triple negative and HER2 subtypes (80% both vs 30% and 48% for luminal A and luminal B p: 0.001). The 2 yr and 5 yr overall survival was 75.0% and 59.3% for luminal A, 71.4% and 55.1% luminal B, 67.7% and 54.9% triple negative, 58.3% and 41.7% HER2 (p: 0.434). The 2 yr progression free survival was 81.6%, 72.6%, 61.5% and 59.4% for each group respectively (p: 0.522). As conclusion, the breast cancer in 35 yr old or less women is uncommon; the triple negative subtype is more common, also in relation with high histological grade and in lower age. The overall survival and the progression free survival are worse in patients with lower age. Citation Format: Morante ZD, Pacheco C, Limón RS, Neciosup S, Gomez HL. Breast cancer in young patients, twelve years of experience in a single institution. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-18.
An Apology
Authors: Lewis Thomas
Journal: New England Journal of Medicine (1976)

The role of the observer in biologic research is complicated but not bizarre: he or she simply observes, describes, interprets, maybe once in a while emits a hoarse shout, but that is that; the act of observing does not alter fundamental aspects of the things observed, or anyway isn't supposed to.It is very different in modern physics. The uncertainty principle doesn't mean that the observer necessarily destroys the precise momentum, or shifts the particle, in the act of observing, although these things happen. It is a more profound effect. The observer and his apparatus create the reality to be . . .
Do Surgeons or Hospital Economics Ultimately Decide Operative Approach?
Authors: Richard S. Matulewicz, Joshua J. Meeks
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Treatment of Adrenogenital Syndrome
Authors: Joseph F. Dingman
Journal: JAMA (1962)

Ten women and 6 children with adrenogenital syndrome were treated with injections of prednisolone trimethylacetate or methylprednisolone acetate at 2- to 3-week intervals for periods of as long as 22 months. Both steroids produced satisfactory adrenal suppression in most patients, but prednisolone trimethylacetate appeared to be slightly more effective than equivalent doses of methylprednisolone acetate in lowering urinary 17-ketosteroids and improving menstrual function in the adults. There was, however, no apparent difference in the therapeutic action of either steroid in the children. The advantage of intermittent parenteral therapy over daily oral therapy in some patients is briefly discussed.
DSM-III implications of the diagnoses of catatonia and bipolar disorder
Authors: R K Ries
Journal: American Journal of Psychiatry (1985)

Although catatonia has traditionally been thought of as a type of schizophrenia, the author presents studies indicating that catatonia may be at least as common in bipolar disorder as it is in schizophrenia. He points out that changing definitions of schizophrenia and affective disorder require a reassessment of catatonia and its incorporation in modern diagnostic systems. The discussion represents material presented at the Affective Disorders Advisory Committee of the American Psychiatric Association Work Group to Revise DSM-III.
Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax
Authors: M Lisovsky, Z Estrov, X Zhang, U Consoli, G Sanchez-Williams, V Snell, R Munker, A Goodacre, V Savchenko, M Andreeff
Journal: Blood (1996)
Abstract B2-10: Systems biology reveals role of cholesterol homeostasis in breast cancer metastasis
Authors: Weina Zhao, Prijic Sara, Bettina Urban, Michael Tisza, Sendurai A. Mani, Jeffrey T. Chang
Journal: Cancer Research (2015)

Abstract New therapeutic targets that can inhibit cancer metastasis are desperately needed. To address this issue, we have leveraged a computational approach and performed an unbiased screen for therapies that can inhibit an epithelial-to-mesenchymal transition (EMT) gene expression profile, a phenotype that is believed to promote metastases. This yielded predictions of drugs that can both promote and inhibit an EMT transcriptional profile. Following up on these predictions, we confirmed experimentally that these drugs can induce or repress an EMT in a range of breast cancer cell lines. Furthermore, we discovered that they do so by altering the fluidity of the plasma membrane. An increase in plasma membrane fluidity is necessary and sufficient to induce and maintain an EMT state, increased motility, and increased mammosphere forming ability. Finally, we found that human cancers can regulate their membrane fluidity through cholesterol homeostasis pathways. Human breast tumors with altered cholesterol profiles have a significantly shorter time to metastasis. These data demonstrate that an unbiased systems approach can be used to discover novel pathways that underlie metastasis. Our multidisciplinary approach combining computational, cell biology, and mouse models reveal that plasma membrane fluidity is a cellular attribute that is leveraged by human tumors to increase metastatic capacity, and that it can, in principle, be targeted by therapeutics to prevent metastasis. Citation Format: Weina Zhao, Prijic Sara, Bettina Urban, Michael Tisza, Sendurai A. Mani, Jeffrey T. Chang. Systems biology reveals role of cholesterol homeostasis in breast cancer metastasis. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr B2-10.
Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone
Authors: E. Diaz-Rubio, J.L. Gonzalez-Larriba, R. Rosell, A. Abad, M. Martin, J.J. Valerdi, J.J. Barriga
Journal: Annals of Oncology (1990)
Abstract SY33-04: Integrated omic analysis of lung cancer reveals metabolism-proteome signatures with prognostic impact
Authors: Michael F. Moran, Lei Li, Yuhong Wei, Paul Taylor, Christine To, Jiefei Tong, Vladimir Ignatchenko, Melania Pintilie, Nhu-An Pham, Wen Zhang, Lakshmi Muthuswamy, Frances A. Shepherd, Thomas Kislinger, Ming S. Tsao
Journal: Cancer Research (2015)

Abstract Cancer results from processes prone to selective pressure and dysregulation acting along the sequence-to- phenotype continuum DNA→RNA→Protein→Disease. An Omics Array integrating DNA gene copy number, mRNA transcriptome, and quantified proteome was assembled into a genetic map representing non-small cell lung carcinoma (NSCLC). Data were collected from patient-matched normal lung, primary tumors, and patient tumor-derived xenograft (PDX) tumors. Dysregulated proteins not previously implicated as cancer drivers were found encoded throughout the genome including but not limited to regions of recurrent DNA amplification/deletion in NSCLC. Unsupervised clustering revealed signatures comprising metabolism proteins particularly highly recapitulated between matched primary and PDX tumors, and which distinguished between the major NSCLC histological subtypes adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Interrogation of The Cancer Genome Atlas (TCGA) revealed sizeable cohorts of NSCLC patients with DNA alterations in genes encoding the metabolism proteome signatures, and accompanied by differences in survival. Similar to the proteome signatures from which they were extrapolated, the gene mutation signatures with prognostic impact discriminated between the lung ADC and SCC subtypes. Serine hydroxymethyltransferase 2 (SHMT2), a key enzyme in serine/glycine and folate- dependent one-carbon metabolism, is upregulated in the proteomes of NSCLC primary and PDX tumours, and is implicated as a driver of recurrent chromosome 12q14.1 amplification in NSCLC. SHMT2, along with other enzymes implicated as anti-folate targets, is also part of a metabolism proteome signature associated with poor outcome in lung ADC. The interrogation of cancer genomes and proteomes for alterations that are related products of selective pressures driving the cancer phenotype may be a general approach to uncover and group together cryptic, polygenic cancer drivers, which might represent new anti-cancer therapeutic targets. Citation Format: Michael F. Moran, Lei Li, Yuhong Wei, Paul Taylor, Christine To, Jiefei Tong, Vladimir Ignatchenko, Melania Pintilie, Nhu-An Pham, Wen Zhang, Lakshmi Muthuswamy, Frances A. Shepherd, Thomas Kislinger, Ming S. Tsao. Integrated omic analysis of lung cancer reveals metabolism-proteome signatures with prognostic impact. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr SY33-04. doi:10.1158/1538-7445.AM2015-SY33-04
Abstract P4-14-09: Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
Authors: RB Mukku, S Verma, J Liu, R Steingart, C Hudis, AF Yu, C Dang
Journal: Cancer Research (2016)

Abstract Background: Trastuzumab (H) improves disease-free survival and overall survival in HER2+ early breast cancer (EBC) but is associated with risk of treatment-induced cardiotoxicity especially when administered after an anthracycline. We performed a single center retrospective study to assess the cardiac safety of adjuvant trastuzumab therapy without anthracyclines in a real-world clinical setting. Methods: Patients (pts) with HER2+ early breast cancer (EBC) who received H without anthracycline-based chemotherapy between January 2010 and June 2014 were studied. Patients enrolled in a clinical trial were excluded. Tumor characteristics, chemotherapy regimen, cardiovascular risk factors, left ventricular ejection fraction (LVEF), and treatment interruption data were collected. A cardiac event (C.E.) was defined as New York Heart Association class III or IV heart failure with LVEF decline of &amp;gt; 10% to &amp;lt; 55% or possible/probable cardiac death, as previously defined by the NSABP B-31 trial. Results: In total, 174 pts with HER2+ EBC treated with H-based therapy without anthracyclines were identified. Median age was 59 years (range, 32 to 85 years), 72 (41%) had hypertension, 55 (32%) had hyperlipidemia, 29 (16%) had diabetes, and 5 (3%) had coronary artery disease. At baseline, all pts had a LVEF &amp;gt; 50% (median, 66%; range, 50% to 81%). Two (1.1%) pts developed a C.E. Both pts had risks factors for C.E. (1 - age &amp;gt; 60 years, hypertension, and prior history of anthracycline exposure; 1- age &amp;gt; 60 years, hypertension, hyperlipidemia, and baseline LVEF of 50-55%). After discontinuation of H, both patients had recovery of LVEF to &amp;gt; 50% and resolution of heart failure symptoms. Twelve (6.9%) pts developed asymptomatic LVEF decline of &amp;gt; 10% points to &amp;lt; 55% during H therapy. Of the 14 patients who developed cardiotoxicity, H was prematurely interrupted or discontinued in 8 patients. Conclusion: In our single center experience of patients being treated off study, the incidence of C.E.s and asymptomatic LVEF decline during H therapy without an anthracycline was 1.1% and 6.9%, respectively. These appeared higher than events reported in clinical trials possibly due to the inclusion of an older group of women with a higher prevalence of cardiovascular risk factors. Overall, the incidence of symptomatic heart failure is low for H without an anthracycline even in this older group. Citation Format: Mukku RB, Verma S, Liu J, Steingart R, Hudis C, Yu AF, Dang C. Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-09.
The Framework Convention on Tobacco Control
Authors: D Satcher
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P2-09-15: Rapid BRCA analysis: Experience of a single institution
Authors: A Mailliez, H Herin, F Revillion, C Adenis, J-P Peyrat, J Bonneterre
Journal: Cancer Research (2016)

Abstract The interest of rapid BRCA analysis, even before the initial treatment could modify the surgical indications (ie total mastectomy and immediate reconstruction even in case where tumorectomy would be suitable). The aim of this study was to evaluate the indications and consequences of this rapid determination of BRCA status in our institution. Patients Rapid BRCA analysis was conducted in 129 patients (pts) treated for breast cancer and addressed to the genetician at Oscar Lambret Center between 2009 and 2014: in 98 pts to discuss breast and axilla surgical modalities, in 4 cases to discuss oophorectomy, in 3 cases to have access to PARP inhibitors. In the other 24 pts, the reasons were debatable: patient leaving abroad, patient requiring reproductive assisted technology..... Results 38 deleterious mutations (29,4%) were identified (31 BRCA1, 7 BRCA2) in 38 pts. Cancer treatment was on going for 107 pts, programmed for 12 pts and finished for 10. The median time between cancer diagnosis and genetic counseling was 81 days (5-5160), between blood sample collection and BRCAs analysis 37 days (13-132), between availability of the laboratory results and the information to the patient: 39 days (1-234); 7 pts (5.4%) never came to obtain the laboratory results. Treatment was modified after genetic counselling for 8 pts out of 119 (7%). Six of them had BRCA1 deleterious mutations. Three decided subsequent radical mastectomy and adjuvant radiation was cancelled, another had a radical mastectomy before radiation, another treated for bilateral breast cancer had a bilateral radical mastectomy before radiation and the last treated for unilateral breast cancer had a bilateral radical mastectomy before radiation. Out of these 8 pts, two did not have a deleterious mutation. One had a bilateral radical mastectomy before laboratory result and one with BRCA variant of unknown significance had a homolateral radical mastectomy. Conclusion discussion Our experience shows that rapid BRCA analysis is feasible. In this selected population the mutation rate is very high. However, first, it appears that indications for rapid BRCA analysis were variable and not always relevant. Second, genetic result impacts on treatment only in 7% of pts. Indications could be justified by the use of PARP inhibitors. Up to now, the indications of rapid genetic analysis are rare. Citation Format: Mailliez A, Herin H, Revillion F, Adenis C, Peyrat J-P, Bonneterre J. Rapid BRCA analysis: Experience of a single institution. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-15.
Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response
Authors: Antoine Obry, Julie Hardouin, Thierry Lequerré, Frédérique Jarnier, Olivier Boyer, Patrice Fardellone, Peggy Philippe, Christian Marcelli, Xavier Le Loët, Olivier Vittecoq, Pascal Cosette
Journal: Theranostics (2015)

Objective:The recent growth of innovating biologics has opened fascinating avenues for the management of patients.In rheumatoid arthritis, many biologics are currently available, the choice of which being mostly determined empirically.Importantly, a given biologic may not be active in a fraction of patients and may even provoke side effects.Here, we conducted a comparative proteomics study in attempt to identify a predictive theranostic signature of non-response in patients with rheumatoid arthritis treated by etanercept/methotrexate combination.Methods: A serum sample was collected prior to treatment exposure from a cohort of 22 patients with active RA.A proteomic "label free" approach was then designed to quantitate protein biomarkers using mass spectrometry.To verify these results, a relative quantification followed by an absolute quantification of interesting protein candidates were performed on a second cohort.The criterion of judgment was the response to etanercept/methotrexate combination according to the EULAR criteria assessed at 6 months of treatment.Results: These investigations led to the identification of a set of 12 biomarkers with capacity to predict treatment response.A targeted quantitative analysis allowed to confirm the potential of 7 proteins from the latter combination on a new cohort of 16 patients.Two highly discriminating proteins, PROS and CO7, were further evaluated by ELISA on this second cohort.By combining the concentration threshold of each protein associated to a right classification (responders vs non-responders), the sensitivity and specificity reached 88.9 % and 100 %, respectively.Conclusion: Prior to methotrexate/etanercept treatment, abundance of several sera proteins, notably PROS and CO7, were associated to response status of RA patients 6 month after treatment initiation.